{"article_id": "CRL_q2_2021.txt", "article": ["we believe we will make these investments and remain well - positioned to achieve our operating margin target of 22.5 % in 2024 .", "quarterly revenue surpassed $ 900 million for the first time and a $ 914.6 million in the second quarter of 2021 , represented a 34 % increase over last year .", "organic revenue growth of 24.1 % was increased by approximately 8 % , when compared to last year 's covid - 19 impact in the second quarter of 2020 , with the greatest impact in the research models and services segment .", "the operating margin was 20.8 % , an increase of 350 basis points year - over - year .", "notwithstanding this favorable year - over - year comparison , we were pleased with the margin progression in the first half of the year and are on track to achieve a full year operating margin of approximately 21 % or 100 basis points higher than last year .", "earnings per share were $ 2.61 in the second quarter , an increase of 65.2 % from $ 1.58 in the second quarter of last year .", "this result widely exceeded our prior outlook of more than 50 % earnings growth for the quarter , primarily as a result of the exceptional demand environment .", "we now expect organic revenue growth in a range of 13 % to 15 % , 100 basis point increase from our prior range .", "non-gaap earnings per share are expected to be in the range from $ 10.10 to $ 10.35 , which represents 24 % to 27 % year - over - year growth and an increase of $ 0.35 at midpoint from our prior outlook .", "revenue was $ 540.1 million in the second quarter , an 18.1 % increase on an organic basis over the second quarter of 2020 , driven by broad - based demand for both discovery and safety assessment services .", "the dsa operating margin increased by 30 basis points to 23.5 % in the second quarter .", "foreign exchange reduced the dsa operating margin by 150 basis points in the quarter as revenue and costs are not naturally hedged at certain dsa sites , including our safety assessment operations in canada .", "we continue to expect the dsa margin will be in the mid-20 % range for the year .", "rms revenue was $ 176.7 million , an increase of 44.5 % on an organic basis over the second quarter of 2020 .", "approximately 33.4 % of this growth was attributable to the comparison to last year 's covid - related revenue impact from client site closures and disruptions , which reduced research model order activity .", "adjusted for the covid impact , the rms growth rate was above 10 % as strong research activity across biopharmaceutical academic and government clients led most rms businesses to grow above their targeted growth rates .", "the rms operating margin increased to 27.4 % from 9.1 % in the second quarter of last year .", "revenue for the manufacturing segment was $ 197.8 million , a 26.6 % increase on an organic basis over the second quarter of last year .", "consistent with the first quarter , microbial solutions growth rate in the second quarter was well above the 10 % level , reflecting strong demand for our endosafe endotoxin testing systems , cartridges , and core reagents in all geographic regions , as well as accugenix microbial identification services .", "the biologics testing business reported another exceptional quarter of strong revenue growth that was well above the 20 % growth target for this business .", "there has been a rapid increase in the number of cell and gene therapy programs in development to approximately 3,000 programs now in the pipeline , with approximately two - thirds in the preclinical phase , which is expected to continue to fuel the strong growth .", "covid - 19 vaccine work was also a meaningful driver of biologics second quarter growth , but the underlying biologics growth trends remained above the 20 % level , even without the incremental covid - 19 testing revenue .", "the manufacturing segment second quarter operating margin declined by 420 basis points to 33.2 % .", "coupled with the addition of vigene in the third quarter , we expect a full year manufacturing margin slightly below the mid-30 % range .", "it will also allow us to achieve our longer - term financial targets of low double - digit organic revenue growth and an average of approximately 50 basis points of operating margin improvement beyond 2021 .", "organic revenue growth of 24.1 % , including 8 % related to last year 's covid - 19 impact and operating margin expansion of 350 basis points , were the primary drivers behind earnings - per - share growth share growth of 65.2 % to $ 2.61 .", "based on our strong second quarter results and expectations for the underlying strength of demand to continue , we have increased our full year financial guidance and now expect to deliver organic revenue growth in a range of 13 % to 15 % for the full year .", "primarily as a result of the enhanced growth prospects this year , and to a lesser extent , a favorable tax rate , we raised our earnings per share guidance by $ 0.35 to a range of $ 10.10 to $ 10.35 , which represents year - over - year growth of 24 % to 27 % .", "including the acquisitions of cognate and , more recently , vigene biosciences , manufacturing 's reported revenue growth rate is expected to be in the low to mid-40 % range .", "with regard to operating margin , our expectations for segment contributions remain mostly unchanged from our prior outlook , with the rms operating margin meaningfully above 25 % for the full year , dsa in the mid-20 % range and manufacturing slightly below the prior mid-30 % outlook , principally reflecting the addition of vigene in late june .", "lower unallocated corporate costs contributed to the second quarter margin expansion , totaling 5.6 % of revenue or $ 51.2 million in the second quarter , compared to 6.1 % of revenue last year .", "we continue to expect unallocated corporate costs to be in the mid -5 % range as a percentage of revenue for the full year .", "the second quarter non-gaap tax rate was 20.4 % , representing a 60 basis point decline from 21 % in the second quarter of last year .", "or the full year , we are reducing our tax rate outlook to a range of 19.5 % to 20.5 % from our prior outlook of a tax rate in the low 20 % range , principally driven by a higher benefit from stock - based compensation .", "total adjusted net interest expense for the second quarter was $ 20.8 million , an increase of $ 3.7 million sequentially and $ 1.7 million year - over - year , due to higher debt balances primarily to fund the cognate acquisition .", "at the end of the second quarter , we had an outstanding debt balance of $ 2.7 billion , representing gross and net leverage ratios of about 2.5 times .", "for the full year , we now expect total adjusted net interest expense to be slightly below our prior outlook in a range of $ 82 million to $ 85 million , primarily reflecting the accelerated debt repayment .", "free cash flow was $ 140.2 million in the second quarter , an increase of 3.5 % over the $ 135.5 million for the same period last year .", "in view of our robust results in the first half of the year , we have increased our free cash flow outlook by $ 65 million and now expect free cash flow of approximately $ 500 million for the full year .", "capex was $ 46.4 million in the second quarter last year , compared to $ 26.8 million last year .", "we continue to expect capex to be approximately $ 220 million for the full year .", "accordingly , we expect organic revenue growth in the low to mid-teens range and reported revenue growth in the low 20 % range .", "we expect low double - digit earnings - per - share growth when compared to last year 's third quarter level of $ 2.33 .", "i will remind you that the dsa operating margin in the third quarter of last year included a 50 basis point benefit from a discovery milestone payment , which will impact the year - over - year comparison ."], "summary_gold": "q2 revenue $ 914.6 million versus refinitiv ibes estimate of $ 880.4 million .<q>q2 non -gaap earnings per share $ 2.61 .<q>increases 2021 guidance .<q>sees fy revenue growth , organic 13 % - 15 % .<q>sees fy non -gaap earnings per share estimate $ 10.10 - $ 10.35 .", "summary_pred": "we continue to expect unallocated corporate costs to be in the mid -5 % range as a percentage of revenue for the full year .<q>the second quarter non-gaap tax rate was 20.4 % , representing a 60 basis point decline from 21 % in the second quarter of last year .<q>the biologics testing business reported another exceptional quarter of strong revenue growth that was well above the 20 % growth target for this business .<q>accordingly , we expect organic revenue growth in the low to mid-teens range and reported revenue growth in the low 20 % range .<q>there has been a rapid increase in the number of cell and gene therapy programs in development to approximately 3,000 programs now in the pipeline , with approximately two - thirds in the preclinical phase , which is expected to continue to fuel the strong growth .<q>adjusted for the covid impact , the rms growth rate was above 10 % as strong research activity across biopharmaceutical academic and government clients led most rms businesses to grow above their targeted growth rates .<q>we expect low double - digit earnings - per - share growth when compared to last year 's third quarter level of $ 2.33 .<q>the manufacturing segment second quarter operating margin declined by 420 basis points to 33.2 % .<q>this result widely exceeded our prior outlook of more than 50 % earnings growth for the quarter , primarily as a result of the exceptional demand environment .<q>the operating margin was 20.8 % , an increase of 350 basis points year - over - year .<q>we believe we will make these investments and remain well - positioned to achieve our operating margin target of 22.5 % in 2024 .<q>foreign exchange reduced the dsa operating margin by 150 basis points in the quarter as revenue and costs are not naturally hedged at certain dsa sites , including our safety assessment operations in canada .", "len_article": 44, "len_summary_gold": 5, "len_summary_pred": 12, "len_sent_scores": 44}